BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a ...

Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit ...

Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A huge leap in fines for misusing mobility parks, help with childcare and access to new drugs are just some of the measures ...

It is the first of a slew of cancer drugs to now funded by Pharmac following the agency's multi-million dollar budget boost.

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumorsPreclinical ...